Publications

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.

Pera B, Krumsiek J, Assouline SE, Marullo R, Patel J, Phillip JM, Roman L, Mann KK, Cerchietti L.  2018.  Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.. EBioMedicine. 28:80-89.

Pera B, Krumsiek J, Assouline SE, Marullo R, Patel J, Phillip JM, Roman L, Mann KK, Cerchietti L.  2018.  Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.. EBioMedicine. 28:80-89.

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov.

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov.

Deb D, Rajaram S, Larsen JE, Dospoy PP, Marullo R, Li L-S, Avila K, Cerchietti L, Xue F, Minna J et al..  2017.  Combination therapy targeting BCL6 and phospho-STAT3 defeats intra-tumor heterogeneity in a subset of non-small cell lung cancers.. Cancer Res.

Deb D, Rajaram S, Larsen JE, Dospoy PP, Marullo R, Li L-S, Avila K, Cerchietti L, Xue F, Minna J et al..  2017.  Combination therapy targeting BCL6 and phospho-STAT3 defeats intra-tumor heterogeneity in a subset of non-small cell lung cancers.. Cancer Res.

Cerchietti L, Melnick A.  2017.  DNA Methylation-Based Biomarkers.. J Clin Oncol. :JCO2016710616.

Du W, Goldstein R, Jiang Y, Aly O, Cerchietti L, Melnick AM, Elemento O.  2017.  Effective combination therapies for B cell lymphoma predicted by a virtual disease model.. Cancer Res.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2017.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.. Leuk Lymphoma. :1-3.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, M Calvo-Vidal N, Chou T, Chow A, Minuesa G, Park SMi et al..  2017.  Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.. Nat Genet. 49(6):866-875.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, M Calvo-Vidal N, Chou T, Chow A, Minuesa G, Park SMi et al..  2017.  Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.. Nat Genet. 49(6):866-875.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, M Calvo-Vidal N, Chou T, Chow A, Minuesa G, Park SMi et al..  2017.  Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.. Nat Genet. 49(6):866-875.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, Phillip J, Pera B, Yang SNing, Takpradit K et al..  2017.  THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.. Nat Commun. 8:14290.

Pera B, Tang T, Marullo R, Yang S-N, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J et al..  2016.  Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.. Clin Epigenetics. 8:79.

Pera B, Tang T, Marullo R, Yang S-N, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J et al..  2016.  Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.. Clin Epigenetics. 8:79.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al..  2016.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al..  2016.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al..  2016.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.